In this episode of Meeting Mic, we bring you pearls and perspectives from the American Society of Retina Specialists Annual Meeting.

In an interview, Anat Loewenstein, MD, MHA, of Tel Aviv Medical Center, talks about how Home OCT combined with an AI analysis helped in the early detection of retinal fluid in patients with age-related macular degeneration.

Next, David Almeida, MD, MBA, PhD, of Erie Retina Research in Pennsylvania, talks about how CG-P5, a topical peptide eye drop, met safety and efficacy endpoints for wet age-related macular degeneration.

Hasenin Al-khersan, MD, discusses findings from a retrospective study on pegcetacoplan slowing photoreceptor and retinal pigment epithelium loss in patients with geographic atrophy only as well as patients with GA and concurrent wet age-related macular degeneration.

Sunir J. Garg, MD, FACS, FASRS, discusses findings from a real-world study about suprachoroidal triamcinolone acetonide having a durable effect in patients with chronic cystoid macular edema.

And, Christina Y. Weng, MD, MBA, FASRS, of Baylor College of Medicine in Houston tells us about her study on systemic statin use reducing the rate of proliferative vitreoretinopathy and reoperation following primary retinal detachment repair by nearly half.

Read the full coverage here:

Home OCT with AI comparable to expert graders in AMD

Loewenstein A. Longitudinal performance of a trend analysis algorithm for home OCT monitoring in neovascular age-related macular degeneration (NVAMD). Presented at: American Society of Retina Specialists annual meeting; July 15-18, 2026; Montreal.

Peptide eye drop shows fluid, thickness reductions in patients with wet AMD

Almeida D, et al. Efficacy and safety of a novel topical peptide (CG-P5) for the treatment of neovascular age-related macular degeneration: Phase 1 results. Presented at: American Society of Retina Specialists annual meeting; July 15-18, 2026; Montréal, Canada

Pegcetacoplan slows photoreceptor, RPE loss in patients with GA and concurrent wet AMD

Al-khersan H. Assessment of geographic atrophy progression following pegcetacoplan in the real world with and without neovascular age-related macular degeneration. Presented at: American Society of Retina Specialists annual meeting; July 15-18, 2026; Montreal.

Suprachoroidal triamcinolone shows durable effect in cystoid macular edema

Garg SJ, et al. Durability and safety of suprachoroidal triamcinolone acetonide in eyes with chronic cystoid macular edema in real-world clinical practice. Presented at: American Society of Retina Specialists annual meeting; July 15-18, 2026; Montreal.

Study: Statin use halves risk for PVR after retinal detachment surgery

Weng CY, et al. Statin use and association with proliferative vitreoretinopathy and reoperation risk following retinal detachment surgery. Presented at: American Society of Retina Specialists annual meeting; July 15-18, 2026; Montreal.

Al-khersan reports consulting for Apellis. Almeida reports being a researcher and consultant for Caregen. Garg reports consulting for Bausch + Lomb. The study was funded by Bausch + Lomb. Loewenstein reports consulting for Notal Vision. Weng reports no relevant financial disclosures.

In this episode of Meeting Mic, Oncology Overdrive host, Shikha Jain, MD, is joined by Akriti Jain, MD, to discuss innovations in the management of acute myeloid leukemia, as well as highlights and abstracts from ASCO Annual Meeting.

· What advances have you seen in AML care over the past 10 to 12 years? 5:57

· How do you manage treatment of patients with TP53-mutated AML? 13:39

· What types of disparities do you see in your patient populations? 15:48

· What advice do you give patients to help them better understand the benefits of clinical trials? 20:51

· What abstracts were you most excited about at ASCO this year? 25:18

· Is personalized care becoming more of a focus in AML management? 27:19

We'd love to hear from you! For more from Dr. Shikha Jain, follow her on X: @ShikhaJainMD and on Instagram: @shikhajainmd. For more from Dr. Akriti Jain, email jaina9@ccf.org.

Shikha Jain reports no relevant financial disclosures. Akriti Jain reports advising/consulting roles with Ascentage Pharma, Daiichi Sankyo, Novartis, Servier, Sobi, Syndax and Takeda, and research funding from Novartis and Servier. She also has served as a speaker for Geron, PharmaEssentia and Rigel Pharmaceuticals.

References:

· Granat LM, et al. Abstract 6587. Presented at: ASCO Annual Meeting; May 29-June 2, 2026; Chicago.

· Pino-Ascencio S, et al. Abstract 6580. Presented at: ASCO Annual Meeting; May 29-June 2, 2026; Chicago.

In this episode of Meeting Mic, we bring you pearls and perspectives in breast cancer from ASCO Annual Meeting.

In an interview, Jame Abraham, MD, discusses the DESTINY-Breast05 study, as well as clinical and demographic risk factors for interstitial lung disease and radiation pneumonitis.

Next, Shimoli Barot, MD, discusses results from the phase 3 lidERA BC clinical trial of premenopausal vs. postmenopausal women with breast cancer.

Sara A. Hurvitz, MD, FACP, provides an overview of the ASCENT-03 study of a subset of women with triple-negative breast cancer.

And, Sherry Shen, MD, talks about a presentation on mutational signatures and related outcomes in metastatic invasive lobular carcinoma.

Read the full coverage here:

VIDEO: Clinicians 'should continue to pay attention' to T-DXd side effects in breast cancer

Untch M, et al. Abstract 516. Presented at: ASCO Annual Meeting; May 29-June 2, 2016; Chicago.

VIDEO: Giredestrant improves breast cancer survival, regardless of menopause status

Healio Interviews

VIDEO: Sacituzumab govitecan delays subsequent therapy in breast cancer subset

Hurvitz SA. Abstract 1001. Presented at: ASCO Annual Meeting; May 29-June 2, 2026; Chicago.

VIDEO: Survival in metastatic invasive lobular carcinoma differs by mutational signature

Shen S, et al. Abstract 1141. Presented at: ASCO Annual Meeting; May 29-June 2, 2026; Chicago.

'Reassuring': Omitting full axillary dissection does not worsen survival in breast cancer

De Boniface J, et al. Abstract LBA503. Presented at: ASCO Annual Meeting; May 29-June 2, 2026; Chicago.

Abraham reports research funding from AstraZeneca/Daiichi Sankyo and Pfizer. Barot and Shen report no relevant financial disclosures. Hurvitz reports research funding from AstraZeneca/Daiichi Sankyo, Novartis and Stemline Therapeutics; and advisory or consulting roles with Akari Therapeutics, ALX Oncology, Bayer, BeOne Medicines, Blueprint Medicines, Boundless Bio, BriaCell, BridgeBio Pharma, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly Oncology, Ellipses Pharma, EMBioSys, Gilead Sciences, Jazz Pharmaceuticals, Luminate Medical, Mersana Therapeutics, Myricx Bio, Prelude Therapeutics and Roche.